KRYS

SEC source: 0001298709-23-000020 · wk-form4_1694555955.xml · nonDerivative · entry 5

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,659,338

F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.

F6 · price: The transaction was executed in multiple trades ranging from $128.7400 to $129.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000020 · wk-form4_1694555955.xml · nonDerivative · entry 4

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,661,448

F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.

F5 · price: The transaction was executed in multiple trades ranging from $127.7350 to $128.7300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000020 · wk-form4_1694555955.xml · nonDerivative · entry 3

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,672,005

F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.

F4 · price: The transaction was executed in multiple trades ranging from $126.7200 to $127.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000020 · wk-form4_1694555955.xml · nonDerivative · entry 2

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,673,878

F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.

F3 · price: The transaction was executed in multiple trades ranging from $125.7200 to $126.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000020 · wk-form4_1694555955.xml · nonDerivative · entry 1

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,679,330

F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.

F2 · price: The transaction was executed in multiple trades ranging from $124.7100 to $125.6950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001711279-23-000057 · wk-form4_1688416274.xml · derivative · entry 1

Sutherland Everett Rand · CIK 0001852880 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period.

SEC source: 0001711279-23-000059 · wk-form4_1688416510.xml · derivative · entry 1

Mazzacco Catherine · CIK 0001967722 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180

Underlying: Common Stock · 2,180 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period.

SEC source: 0001711279-23-000055 · wk-form4_1688416054.xml · derivative · entry 1

ROSSI DINO A · CIK 0001209059 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period.

SEC source: 0001711279-23-000053 · wk-form4_1688415856.xml · derivative · entry 1

Mason Christopher · CIK 0001836440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period.

SEC source: 0001711279-23-000051 · wk-form4_1688415647.xml · derivative · entry 1

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period.

SEC source: 0001711279-23-000049 · wk-form4_1688415354.xml · derivative · entry 1

Gangolli Julian S · CIK 0001532023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,800

Underlying: Common Stock · 6,800 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period.

SEC source: 0001860010-23-000004 · wk-form4_1686351600.xml · derivative · entry 5

ORTH ANDREW C. · CIK 0001860010 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 12,500 shares

Expires 2032-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.

F5 · derivative.exercise_date: 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.

SEC source: 0001860010-23-000004 · wk-form4_1686351600.xml · nonDerivative · entry 4

ORTH ANDREW C. · CIK 0001860010 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.

F4 · price: The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001860010-23-000004 · wk-form4_1686351600.xml · nonDerivative · entry 3

ORTH ANDREW C. · CIK 0001860010 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 433

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.

F3 · price: The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001860010-23-000004 · wk-form4_1686351600.xml · nonDerivative · entry 2

ORTH ANDREW C. · CIK 0001860010 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,339

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.

F2 · price: The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001860010-23-000004 · wk-form4_1686351600.xml · nonDerivative · entry 1

ORTH ANDREW C. · CIK 0001860010 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 9

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 107,362

F7 · price: The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 8

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 117,362

F6 · price: The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 7

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 122,362

F5 · price: The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 6

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 126,297

F4 · price: The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 5

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 131,297

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 4

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 141,297

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 3

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 146,297

F3 · price: The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 2

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 151,685

F2 · price: The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 1

JANNEY DANIEL · CIK 0001198325 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P.

Disclosed balance after: 152,758

F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 6

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,684,338

F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.

F7 · price: The transaction was executed in multiple trades ranging from $117.5500 to $117.7200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 5

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,684,738

F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.

F6 · price: The transaction was executed in multiple trades ranging from $116.5200 to $117.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 4

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,690,454

F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.

F1 · price: The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 3

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,624,206

F3 · price: The transaction was executed in multiple trades ranging from $117.5500 to $117.6000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 2

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,624,506

F2 · price: The transaction was executed in multiple trades ranging from $116.5200 to $117.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 1

Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,629,063

F1 · price: The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000018 · wk-form4_1685744452.xml · nonDerivative · entry 6

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,624,206

F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma Krishnan.

F7 · price: The transaction was executed in multiple trades ranging from $117.5500 to $117.6000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-23-000018 · wk-form4_1685744452.xml · nonDerivative · entry 5

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,624,506

F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma Krishnan.

F6 · price: The transaction was executed in multiple trades ranging from $116.5200 to $117.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-23-000018 · wk-form4_1685744452.xml · nonDerivative · entry 4

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,629,063

F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma Krishnan.

F1 · price: The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

SEC source: 0001298709-23-000018 · wk-form4_1685744452.xml · nonDerivative · entry 3

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,684,338

F3 · price: The transaction was executed in multiple trades ranging from $117.5500 to $117.7200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000018 · wk-form4_1685744452.xml · nonDerivative · entry 2

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,684,738

F2 · price: The transaction was executed in multiple trades ranging from $116.5200 to $117.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001298709-23-000018 · wk-form4_1685744452.xml · nonDerivative · entry 1

Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,690,454

F1 · price: The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · derivative · entry 21

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 12,500 shares

Expires 2032-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share.

F13 · derivative.exercise_date: 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · derivative · entry 20

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2030-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

F12 · derivative.exercise_date: 50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 17

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,556

F10 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share.

F11 · price: The transaction was executed in a single trade.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 16

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 15

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,556

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

F9 · price: The transaction was executed in multiple trades ranging from $109.9700 to $110.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 14

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,710

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 13

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,556

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

F8 · price: The transaction was executed in multiple trades ranging from $108.9000 to $109.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 12

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,511

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 11

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,556

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

F7 · price: The transaction was executed in multiple trades ranging from $107.6900 to $108.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 10

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,856

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 9

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,556

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

F6 · price: The transaction was executed in multiple trades ranging from $106.3700 to $107.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 8

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,126

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

SEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 7

Romano Kathryn · CIK 0001801385 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,556

F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.

F5 · price: The transaction was executed in multiple trades ranging from $105.3400 to $106.3100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.